Test Price
5,000 AED✅ Home Collection Available
Combined Whole Exome Sequencing (WES) and Chromosomal Microarray (CMA) in UAE | 5000 AED | 2026 DHA Guidelines
تحليل تسلسل الإكسوم الكامل مع المصفوفات الصبغية الدقيقة في الإمارات | 5000 درهم | معتمد من هيئة الصحة بدبي
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139). Dual‑platform confirmation for all pathogenic variants.
- ✓ Premium Logistics: Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain Logistics. VIP Mobile Phlebotomy available 8 AM – 11 PM, sample transport at 2–8°C.
- ✓ Clinical Guidance: Telephonic Post‑Test Clinical Guidance by a DHA‑licensed genetic counsellor to interpret findings and plan next steps.
- ✓ Insurance & Billing: Direct Billing Verification via WhatsApp +971545488731. Pre‑approval support for major UAE insurers.
Overview – Diagnostic Precision for Hereditary & Chromosomal Disorders
Combining Whole Exome Sequencing (WES) and Chromosomal Microarray (CMA) identifies both single‑nucleotide variants and copy‑number changes in a single workflow, delivering the highest diagnostic yield for paediatric neurodevelopmental delay, dysmorphic syndromes, and hereditary cancer predisposition. يجمع الفحص بين تقنيتين متكاملتين لتحقيق أعلى نسبة كشف للتشوهات الوراثية والصيغ الصبغية، وهو الخيار الأول للأطباء السريريين في الإمارات.
| Parameter | Our Combined WES + CMA | WES Only (Closest Alternative) |
|---|---|---|
| Methodology | NGS (Illumina NovaSeq) Exome Capture + Affymetrix CytoScan HD Array | NGS Exome Capture only |
| Resolution | Single‑nucleotide variants, indels, CNVs ≥25 kb, AOH regions | SNVs/indels; limited CNV detection |
| Diagnostic Yield (Neurodevelopmental) | ~45–50% | ~30–35% |
| Turnaround Time | 14–21 days | 14–21 days |
| Clinical Utility in UAE | DHA‑recommended for global developmental delay, multiple congenital anomalies, cancer predisposition | Mainly for suspected monogenic disorders |
Physician Insight & Safety Protocol
“As a clinical geneticist, I consider the parallel whole exome and microarray approach indispensable when a child presents with developmental regression and dysmorphic features that do not fit a single syndrome. It spares families a prolonged diagnostic odyssey and often unveils actionable findings that guide targeted therapies. However, all results require correlation with the patient’s full clinical picture – a normal report does not rule out all genetic conditions, and an abnormal result must be confirmed and interpreted within the clinical context.”
— Dr. Prabhakar Reddy, DHA License: 61713011
Safety Exclusion Criteria & Emergency Red Flags
- This test is not a substitute for acute medical evaluation; if the patient has sudden neurological deterioration, seizures, or loss of consciousness, proceed to the nearest ER immediately.
- Combined WES + CMA is intended for germline (constitutional) genetic analysis. It should not be used for somatic tumour profiling or minimal residual disease monitoring.
- Do not order for low‑risk population screening without pre‑/post‑test genetic counselling.
- Inform the laboratory of any recent blood transfusions or allogeneic bone marrow transplants – these may interfere with germline DNA results.
⚠️ Medication Warning: Do not discontinue or adjust any prescribed medication without explicit instruction from your treating physician. Genetic results may have implications for certain therapies, but changes must be supervised by your specialist.
Patient FAQ & Clinical Guidance
Q: What is the key difference between whole exome sequencing and chromosomal microarray, and why are they combined?
Snippet Answer: Whole exome sequencing reads the protein‑coding regions of all ~20,000 genes to detect tiny spelling mistakes, while microarray scans the entire genome for large deletions or duplications – together they catch almost every clinically relevant genetic change in one.
س: هل يحتاج الفحص إلى تحضيرات خاصة قبل سحب العينة؟
الإجابة المختصرة: لا يحتاج المريض للصيام أو التوقف عن الأدوية، ولكن يُنصح بإبلاغ فريق التمريض بأي أدوية مميعة للدم أو عمليات نقل دم حديثة لضمان جودة العينة.
Q: How long does it take to receive the combined WES + CMA report, and who will explain the results?
Snippet Answer: The final integrated report is typically ready within 14 to 21 calendar days, and a DHA‑licensed genetic counsellor will schedule a complimentary tele‑consultation to walk you through every finding.
Regulatory Compliance:
This service adheres to UAE Federal Decree‑Law No. 41 of 2024 (Art. 87) on Medical Laboratories, the 2026 Clinical Diagnostic Services Law (CDS) for Minors, and the UAE Personal Data Protection Law (PDPL). All genetic data is stored on encrypted servers within the UAE.
Laboratory ISO 9001:2015 Certified – Cert: INT/EGQ/2509DA/3139. Facility License No: 9834453. WhatsApp Support: +971545488731.
ICD‑10 Codes for Medical Records: Z13.79 (Encounter for screening for genetic and chromosomal anomalies), Q99.9 (Chromosomal abnormality, unspecified), Z15.09 (Genetic susceptibility to other malignant neoplasm). LOINC® Code: 81247‑2 (Genetic variant analysis panel) – https://loinc.org/81247-2/.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians